Ceribell
Ceribell's revenue rose 36.1% to $89 million in fiscal 2025. Its operating margin was −65.6%, down from −60.7% a year earlier. Free cash flow was −$42 million. The diluted share count rose 205.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Ceribell does
Ceribell makes a portable system that records the brain's electrical activity, called an EEG, at the bedside of seriously ill hospital patients. Its main use is finding seizures, which in hospital patients often show no physical signs. The Ceribell System has a disposable headband or headcap, a pocket-sized battery-powered recorder, a web portal where neurologists view the signals and software that uses artificial intelligence to flag seizure activity.
Ceribell says conventional EEG machines need specialized technicians and a long setup, which delays diagnosis. It says its system can be put on by any healthcare worker after about one hour of training. Its customers are hospitals, and it says more than 600 hospitals had adopted it by the end of 2025.
It makes money in two recurring ways: it sells the single-use headbands and headcaps, and it charges hospitals a monthly subscription fee for the software, recorders and portal. Its seizure-detection software, called Clarity, got US Food and Drug Administration clearance in May 2023 for adults at risk of seizure. Ceribell says it competes with conventional EEG and other technologies, and it has a history of net losses.
Its biggest risks, as it describes them
- A history of net losses, and a limited operating history with rapid growth that may strain its resources.
- Relying on sales of one system, so hospitals not adopting it or losing confidence in it would hurt it.
- Competition from established companies and from other technologies for detecting seizures.
- Relying on manufacturing and supply chains abroad, and on trade policies and tariffs.
- Hospitals and doctors not being reimbursed enough for tests that use its products.
Income statement
Ceribell lost money in fiscal 2025: a net loss of $53 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 34 | 194 | 159 |
| Debt incl. finance leases | — | — | 20 |
| Net debt (negative means net cash) | — | — | −140 |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | — | 0.1x |
| Interest coverage | −14.3x | −19.9x | −30.9x |
| Current ratio | 2.4x | 16.7x | 9.7x |
| Quick ratio | 2.1x | 16.2x | 9.3x |
Cash flow
Projections
Project Ceribell's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Ceribell says to expect
- Full year 2026: revenue
Ceribell is raising its revenue guidance for the full year 2026 to a range of $115 million to $117 million, representing growth of approximately 29% to 31% over the Company’s prior year revenue.
Insider trades
No officer, director or 10% owner of Ceribell reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | — |
| Rule of 40 | −10.9% | −10.6% |
| Altman Z'' | 8.21 | 3.97 |
| Accruals ratio | −3.8% | −6.0% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | Fail | Fail |
| Cash from operations is positive | Fail | Fail |
| Return on assets rose | — | Pass |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | — |
| Current ratio rose | Pass | Fail |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | Pass | Pass |
| Revenue rose relative to assets | — | Fail |
| F-score | — | — |
Compare
Put Ceribell side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Ceribell | FY25 | 36.1% | −65.6% | −46.7% | — | — | — | |
| Delcath Systems | FY25 | 129.1% | 0.8% | 24.6% | 2.8% | −101.4x | 6 | Compare |
| IRADIMED | FY25 | 14.4% | 31.2% | 20.5% | — | — | — | Compare |
| Kestra Medical Technologies | FY26 | 59.0% | −141.6% | −122.6% | — | — | 4 | Compare |
| Butterfly Network | FY25 | 19.0% | −88.5% | −16.4% | — | — | — | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 45 | 65 | 89 |
| Revenue growth | — | 44.7% | 36.1% |
| Gross profit | 38 | 57 | 78 |
| Research and development | 9 | 14 | 19 |
| Operating income | −30 | −40 | −58 |
| Net income | −30 | −40 | −53 |
| Diluted EPS (US$) | −5.56 | −3.39 | −1.46 |
| Diluted shares (millions) | 5 | 12 | 36 |
| Cash flow | |||
| Cash from operations | −29 | −35 | −41 |
| Capital expenditure | 1 | 1 | 1 |
| Free cash flow | −30 | −36 | −42 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 3 | 5 | 12 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 34 | 194 | 159 |
| Debt incl. finance leases | — | — | 20 |
| Total assets | 59 | 225 | 196 |
| Total liabilities | 24 | 34 | 40 |
| Shareholders' equity | −112 | 191 | 155 |
| Margins and ratios | |||
| Gross margin | 84.4% | 86.7% | 87.9% |
| Operating margin | −66.4% | −60.7% | −65.6% |
| Net margin | −65.2% | −61.8% | −60.0% |
| Free cash flow margin | −66.7% | −55.6% | −46.7% |
| Rule of 40 (growth + FCF margin) | — | −10.9% | −10.6% |
| Return on capital | — | — | — |
| Return on equity | — | −102.5% | −30.8% |
| Return on assets | — | −28.5% | −25.4% |
| Net debt to EBITDA | — | — | — |